Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Diabetic Macular Edema Clinical Trial

— DETeR  

Official title:

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04563299
• Other study ID #: DETeR
• Status: Terminated
• Phase: Phase 4
• Start date: December 9, 2020
• Est. completion date: February 14, 2023

Study information

• Verified date: February 2023
• Source: Retina Vitreous Associates of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections. Patients will be randomized into two cohorts (Cohort 1 and Cohort 2) and then followed for 3 consecutive injection visits. Treatment will be rendered at each injection visit based on the individualized routine established anti-VEGF injection interval for each patient.

Description:

This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections. Patients will be randomized into two cohorts (Cohort 1 and Cohort 2) and then followed for 3 consecutive injection visits. Treatment will be rendered at each injection visit based on the individualized routine established anti-VEGF injection interval for each patient. Within the respective cohorts, one eye per patient will be randomized to receive either an intracanalicular dexamethasone insert or the control treatment at each injection visit. Cohorts are as follows: Cohort 1: Total N= 40 eyes (20 patients). Twenty eyes (one eye per patient) will be randomized to receive an intracanalicular dexamethasone insert. The contra-lateral eye (Control) will receive a sham dilation. Cohort 2: Total N= 40 eyes (20 patients). Twenty eyes (one eye per patient) will be randomized to receive an intracanalicular dexamethasone insert. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week). In eyes randomized to either DEXTENZA or sham dilation, DEXTENZA insertion or sham dilation will be performed prior to injection. In eyes randomized to either DEXTNEZA or topical steroids, eyes randomized to DEXTENZA will receive insertion prior to injection. Eyes randomized to topical steroid therapy (Control) will receive 1 drop of prednisolone acetate 1% pre-injection and the remaining 3 drops of prednisolone acetate 1% post injection. Control eyes will follow tapered dosing over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week) to ensure dose matching between DEXTENZA and Control in Cohort 1. Pain will be rated at 6 time points: (1) prior to any treatment, (2) after anesthesia, (3) after intravitreal injection, (4) 6 hours by telephone (+/- 2 hours), (5) 24 hours by telephone (+/-3 hours) and (6) 3-6 days at assessment visit. Pain will be evaluated by survey administrators masked to treatment assignment. Patient comfort (right eye vs left eye) will be assessed at each patient visit by masked survey administrator. Anterior cell count and anterior cell flare assessment will be conducted at 3-6 days following each intravitreal injection visit. There will be a final patient preference survey performed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: February 14, 2023
• Est. primary completion date: February 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible

for inclusion in the study:

• Patients diagnosed with neovascular AMD, DME or macular edema secondary to RVO undergoing anti-VEGF injections in both eyes.
• > 18 years old
• Able to provide signed written consent prior to participation in any study-related procedures. Exclusion Criteria: A patient who meets any of the following criteria will be excluded from

the study:

• Prescription and OTC ophthalmic mast cell stabilizers and antihistamines within 21 days prior to Screening and throughout the study period (systemic mast cell stabilizers are allowed, and systemic antihistamines are permitted)
• Use of any topical prescription ophthalmic medications (including cyclosporine [Restasis®, Cequa®] or topical lifitegrast [Xiidra®], steroids, nonsteroidal anti- inflammatory drugs [NSAIDs]within 7 days or during study period
• Participation in any drug or device clinical investigation within 30 days prior to study entry and/or during the study period.
• Anterior chamber cells present at time of enrollment
• History of cauterization of the punctum
• Any punctum inflammation or dacryocystitis

Related Conditions & MeSH terms

• Diabetic Macular Edema
• Inflammation
• Macular Degeneration
• Macular Edema
• Neovascular Age-related Macular Degeneration
• Retinal Vein Occlusion

Intervention

Drug:
• Dextenza 0.4Mg Ophthalmic Insert
All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
• Prednisolone Acetate
All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).

Locations

Country	Name	City	State
United States	Retina Vitreous Associates of Florida	Saint Petersburg	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Retina Vitreous Associates of Florida	Ocular Therapeutix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Pain Scores	As measured by a 10-point standardized pain scale (1 = no pain, 10 = worst pain)	As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3
Secondary	Overall Proportion of Eyes with Absence of AC Cell/Flare (Score of 0)	As measured using SUN criteria	Assessed 3-6 days following Injection Visit 1, Injection Visit 2, and Injection Visit 3
Secondary	Proportion of eyes with absence of AC cells/flare (score of 0)	As measured using SUN criteria	Assessed at 3-6 days following Injection Visit 1, Injection Visit 2, and Injection Visit 3 by anti-VEGF type (ranibizumab, aflibercept, brolucizumab, or bevacizumab)
Secondary	Correlation of pain scale outcomes with absence or presence of AC cell count and flare scores	As measured using pain scale outcomes with absence or presence of AC cell count and flare scores	Assessed at 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3
Secondary	Mean Change in pain scores	As measured by a 10-point standardized pain scale (1 = no pain, 10 = worst pain)	As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3
Secondary	Patient Comfort	As measured by masked survey administrator	As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3
Secondary	Mean Change in Tear Break-up Time	As measured by the tear break-up time	As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, Injection Visit 3, and the Final Post-Injection Follow-up Visit (up to 24 weeks)
Secondary	Mean Change in Snellen and Pinhole Acuity	As measured by the ETDRS visual acuity chart	As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, and Injection Visit 3, and the Final Post-Injection Follow-up Visit (up to 24 weeks)
Secondary	Mean change in IOP	As measured by using a Tono-pen	As assessed at Baseline Visit, Injection Visit 1, Injection Visit 2, and Injection Visit 3, and the Final Post-Injection Follow-up Visit (up to 24 weeks)
Secondary	Patient Preference	As measured by modified COMTOL	As assessed at the Final Post-Injection Follow-up Visit (up to 24 weeks)
Secondary	Incidence and severity of adverse events	As measured by the incidence and severity of adverse events	As assessed at Baseline, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3, and the Final Post-Injection Follow-up Visit (up to 24 weeks)